Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lidocaine topical spray - Andros Pharmaceuticals

Next Previous
Drug Profile

Lidocaine topical spray - Andros Pharmaceuticals

Alternative Names: APC 101 - Andros Pharmaceuticals; APC-101; Lidocaine spray 5% solution

Latest Information Update: 27 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Andros Pharmaceuticals
  • Class Acetanilides; Amines; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Postherpetic neuralgia

Most Recent Events

  • 20 May 2026 Andros Pharmaceuticals plans a phase II/III trial in Postherpetic-neuralgia in USA and Australia (Topical) in August 2026 (NCT07599800)
  • 12 Dec 2022 Lidocaine topical spray is still in phase-II trials for Postherpetic neuralgia in Australia (Andros Pharmaceuticals pipeline; December 2022)
  • 28 Mar 2020 No recent reports of development identified for preclinical development in Postherpetic-neuralgia in Taiwan (Topical, Spray)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top